Key Takeaways
- Shares of Novartis climbed nearly 5% following successful Phase 3 trial outcomes for its experimental oral multiple sclerosis treatment remibrutinib
- The drug outperformed Sanofi’s teriflunomide (marketed as Aubagio) in decreasing relapse frequency among relapsing MS patients
- Remibrutinib demonstrated significant benefits in delaying disability progression while maintaining a favorable liver safety profile
- The pharmaceutical giant temporarily halted eight clinical studies involving rap-cel, an experimental CAR-T therapy, following three patient fatalities caused by severe immune complications
- Oncology trials remain unaffected by the rap-cel suspension; Novartis intends to pursue worldwide regulatory clearance for remibrutinib
Shares of Novartis experienced a substantial rally of nearly 5% during early Tuesday trading sessions following the pharmaceutical company’s announcement of encouraging outcomes from two Phase 3 clinical studies evaluating remibrutinib, its investigational oral therapy for multiple sclerosis.
The clinical studies, designated REMODEL-1 and REMODEL-2, evaluated remibrutinib’s performance against teriflunomide, a currently marketed oral MS medication commercialized by Sanofi as Aubagio. The experimental therapy achieved superior results on the principal endpoints across both investigations.
Remibrutinib exhibited superiority compared to teriflunomide in minimizing relapse frequency among adult subjects diagnosed with relapsing multiple sclerosis (RMS). The therapy additionally demonstrated substantial clinical benefit in decelerating the progression of disability.
According to Novartis, remibrutinib maintained a favorable tolerability profile throughout both clinical trials. Notably, researchers observed no hepatic safety signals, aligning with data gathered from preliminary-phase investigations.
Shreeram Aradhye, Novartis’s president of development and chief medical officer, highlighted the continuing unmet medical need in this therapeutic area. He emphasized that patients require oral treatment alternatives capable of providing robust relapse prevention and delayed disability progression while maintaining acceptable safety profiles.
“The positive REMODEL results underscore the potential of remibrutinib as a high-efficacy oral therapy for people living with RMS with a differentiated benefit-risk profile,” Aradhye said.
The company announced intentions to submit regulatory applications for remibrutinib approval worldwide. Comprehensive trial findings will be disclosed at a forthcoming medical conference scheduled in Toronto.
CAR-T Therapy Suspension Casts Shadow
Coinciding with the multiple sclerosis breakthrough announcement, Novartis disclosed that it had suspended eight clinical investigations involving rap-cel, a distinct experimental cellular therapy, in late August following three patient deaths attributed to a dangerous, potentially fatal immune system response.
The suspension took effect on August 24. According to Novartis, the fatalities resulted from a condition characterized by excessive immune system activation leading to organ damage, a recognized complication associated with CAR-T therapies.
Rap-cel represents a CAR-T therapeutic approach that engineers patients’ immune cells to identify and eliminate designated target cells. The suspended trials encompassed autoimmune conditions including systemic lupus erythematosus, rheumatoid arthritis, and vasculitis, along with neurological disorders such as multiple sclerosis and myasthenia gravis.
The pharmaceutical company stated it is performing a comprehensive safety analysis and collaborating with independent safety monitoring boards to determine the root cause and establish protocols for earlier detection of serious adverse events.
Oncology Studies Remain Active
Novartis clarified that its two active trials evaluating rap-cel in lymphoma and leukemia populations were unaffected by the suspension. The company indicated it is maintaining transparent communication with regulatory agencies and continuing surveillance of patients who previously received the experimental treatment.
The Wall Street Journal initially disclosed the trial suspension. The publication additionally reported that Bristol Myers Squibb had implemented precautionary pauses in comparable CAR-T studies targeting autoimmune diseases. Bristol Myers Squibb declined to provide commentary.
Notwithstanding the rap-cel development, market participants concentrated on the promising remibrutinib data. Novartis stock traded approximately 4% higher on Tuesday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
